Clinical Data Pepaxti study supports use in wider myeloma population PharmaTimesPhase 2 bridge data show consistent outcomes in patients with impaired kidney functionOncologyRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) PharmaTimes Phase 2 bridge data show consistent outcomes in patients with impaired kidney function Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Beam one-ups Wave as both show promise of genetic editing for AATDNext: Pazdur declines to announce candidacy for vacated FDA commissioner role Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
